← Policy & Regulation-Standards & approvals (all topics)
US FDA warning letters & import alerts
What it is
The escalation ladder after a USFDA site inspection: Form 483 observations, then a Warning Letter citing CGMP violations, then Import Alert 66-40, which lets US border officials detain that site's shipments without physical examination
Action is facility-specific rather than company-wide, and a site stays listed until the letter is closed out - typically a multi-year remediation
Impact on industries
- Enforcement has intensified - 303 drug and biologics warning letters in FY2025, up ~59% from 190 in FY2024, with no slowdown through 2026
- Data integrity is the India-specific problem: falsified or destroyed records appear in ~60% of letters to Indian sites, questioning the validity of US filings
- Impact is immediate - an alert has covered 11 distributed products at one Indian plant, and 2026 cases show sites listed before the letter was even issued
- Site-specific action and shortage exemptions let multi-plant players shift volumes; single-plant and standalone API firms can lose US revenue entirely